Literature DB >> 623695

Muscle disease in progressive systemic sclerosis: diagnostic and therapeutic considerations.

P J Clements, D E Furst, D S Campion, A Bohan, R Harris, J Levy, H E Paulus.   

Abstract

Upon careful examination, 23 of 24 patients with progressive systemic sclerosis (PSS) were found to have abnormalities of muscle. Nineteen patients presented a homogenous pattern of muscle abnormalities, which untreated was associated with a stable course ("simple myopathy"). Three patients demonstrated inflammatory muscle disease indistinguishable from polymyositis while a fourth patient developed marked weakness associated with a generalized neuropathic process. Muscle enzymes, electromyogram, and muscle biopsy permitted distinction among the different muscle disorders, a distinction that could have prognostic and therapeutic importance.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 623695     DOI: 10.1002/art.1780210111

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  24 in total

1.  Acute myositis in a patient with systemic sclerosis after the administration of darbepoetin alpha.

Authors:  C Palazzi; L D'Agostino; S D'Angelo; A Petricca; I Olivieri
Journal:  Rheumatol Int       Date:  2007-08-03       Impact factor: 2.631

2.  Up regulated expression of tumour necrosis factor {alpha} converting enzyme in peripheral monocytes of patients with early systemic sclerosis.

Authors:  T Bohgaki; Y Amasaki; N Nishimura; M Bohgaki; Y Yamashita; M Nishio; K-I Sawada; S Jodo; T Atsumi; T Koike
Journal:  Ann Rheum Dis       Date:  2005-08       Impact factor: 19.103

3.  Esophageal motility in progressive systemic sclerosis (PSS). Comparison of cine-radiographic and manometric evaluation.

Authors:  P J Clements; B Kadell; A Ippoliti; M Ross
Journal:  Dig Dis Sci       Date:  1979-08       Impact factor: 3.199

Review 4.  Imaging features of musculoskeletal involvement in systemic sclerosis.

Authors:  Nathalie Boutry; Eric Hachulla; Claire Zanetti-Musielak; Mélanie Morel; Xavier Demondion; Anne Cotten
Journal:  Eur Radiol       Date:  2006-09-23       Impact factor: 5.315

5.  Corticosteroid induced remission of oesophageal involvement in mixed connective tissue disease.

Authors:  A Pines; N Kaplinsky; E Goldhammer; J Bregman; O Frankl
Journal:  Postgrad Med J       Date:  1982-05       Impact factor: 2.401

6.  Seizures in systemic sclerosis.

Authors:  Fernando Glasner Araújo; Tiago Nardi Amaral; Simone Appenzeller; Jozélio Freire de Carvalho
Journal:  Rheumatol Int       Date:  2012-12-29       Impact factor: 2.631

7.  Histopathological findings in systemic sclerosis-related myopathy: fibrosis and microangiopathy with lack of cellular inflammation.

Authors:  Claudio Corallo; Maurizio Cutolo; Nila Volpi; Daniela Franci; Margherita Aglianò; Antonio Montella; Chiara Chirico; Stefano Gonnelli; Ranuccio Nuti; Nicola Giordano
Journal:  Ther Adv Musculoskelet Dis       Date:  2016-10-03       Impact factor: 5.346

8.  Clinical and laboratory features of scleroderma patients developing skeletal myopathy.

Authors:  Yoshihiro Mimura; Hironobu Ihn; Masatoshi Jinnin; Yoshihide Asano; Kenichi Yamane; Kunihiko Tamaki
Journal:  Clin Rheumatol       Date:  2004-08-20       Impact factor: 2.980

9.  Course of dermal ulcers and musculoskeletal involvement in systemic sclerosis patients in the scleroderma lung study.

Authors:  Karen Au; Maureen D Mayes; Paul Maranian; Philip J Clements; Dinesh Khanna; Virginia D Steen; Donald Tashkin; Michael D Roth; Robert Elashoff; Daniel E Furst
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-12       Impact factor: 4.794

10.  Measurement of clinical change in progressive systemic sclerosis: a 1 year double-blind placebo-controlled trial of N-acetylcysteine.

Authors:  D E Furst; P J Clements; R Harris; M Ross; J Levy; H E Paulus
Journal:  Ann Rheum Dis       Date:  1979-08       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.